Could a common heartburn pill boost chemo against tough prostate cancer?
NCT ID NCT04337580
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help control advanced prostate cancer that has stopped responding to other treatments. About 50 men with castration-resistant prostate cancer will receive either omeprazole plus cabazitaxel or omeprazole plus docetaxel. The goal is to see if the combination shrinks tumors or slows cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION RESISTANT PROSTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
W.G. Bill Hefner VA Medical Center
RECRUITINGSalisbury, North Carolina, 28144, United States
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?